Puretech Health Sustainability Profile
PureTech Health, a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for complex diseases. Founded in 2015, PureTech has established itself as a leader in the healthcare industry, with a strong emphasis on advancing drug development in areas such as neuroscience, immunology, and gastrointestinal health. The company is renowned for its unique approach to drug discovery, leveraging its proprietary platform to identify and develop novel therapeutics. With a robust pipeline of products, including treatments for neurodegenerative disorders and immune-mediated diseases, PureTech Health is well-positioned in the market. Its commitment to addressing unmet medical needs has garnered recognition, making it a notable player in the biopharmaceutical landscape.
DitchCarbon Score
How does Puretech Health's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Puretech Health's score of 43 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Puretech Health's reported carbon emissions
In 2023, PureTech Health reported total carbon emissions of approximately 276,200 kg CO2e. This figure includes 3,900 kg CO2e from Scope 1 emissions, 57,000 kg CO2e from Scope 2 emissions (market-based), and 107,700 kg CO2e from Scope 3 emissions. The combined Scope 1 and 2 emissions totalled about 168,500 kg CO2e. Comparatively, in 2022, the company’s total emissions were significantly higher at about 665,000 kg CO2e, with Scope 1 emissions at 10,600 kg CO2e, Scope 2 emissions at 402,600 kg CO2e (market-based), and Scope 3 emissions at 251,900 kg CO2e. This indicates a substantial reduction in total emissions year-on-year. PureTech Health has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data is not cascaded from any parent organisation, and all reported figures are derived directly from PureTech Health plc. Overall, while PureTech Health has made progress in reducing its carbon footprint, further commitments and targets would enhance its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 33,300 | 00,000 | 00,000 | 000,000 | 00,000 | 0,000 |
| Scope 2 | 178,800 | 000,000 | 000,000 | 000,000 | 000,000 | 00,000 |
| Scope 3 | 1,199,900 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
How Carbon Intensive is Puretech Health's Industry?
How Carbon Intensive is Puretech Health's Location?
Puretech Health's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Puretech Health has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
